The anatomy of the current antibiotic shortage – more details


Mar 27, 2023

Why does the world seem to suddenly be fighting over antibiotics?

A new study around Peter Klimek of the Complexity Science Hub and the ASCII provides insights.

In the interactive visualization, created by Liuhuaying Yang of the Complexity Science Hub, you can explore the connections and interdependencies for yourself. This video shows how it works.

Antibiotics Shortage © Complexity Science Hub/Yang

The concentration of the market on China and India

1. There is a clear trend of increasing concentration of production in a few countries, namely China and India: The development of production concentration accelerated during the pandemic. Systemic trade risk indicators for China and India show sharp increases after 2018. These dependencies are not directly visible in import relationships but can be unravelled by tracing the production processes backwards along the antibiotics value chain.

 

2. The production concentration is more pronounced in upstream stages of the value chain (intermediaries and active pharmaceutical ingredients, APIs) rather than in downstream stages like unpackaged and packaged products. 76% of the manufacturing sites of intermediaries are located in China and India. 59% of API (active pharmaceutical ingredients) producers are situated in these countries.

 

3. Due to a higher production concentration in intermediaries and APIs, shocks affect APIs more strongly than packaged products. Hence, it becomes harder to find suitable substitutes when confronted with a shortage. In line with this observation, the estimated number of shortages that could be resolved by substitution halved in 2020. Negative impacts on patient care increased.

 

4. The data suggests a tendency towards market segmentation in which firms in European and North American countries developed an increasing dependence on Chinese suppliers. Indian producers trade mostly with local neighbours in Asia, Oceania and African countries.

SARS-CoV-2 led to reduced need for antibiotics

1. When the pandemic hit, non-pharmacological interventions aimed at curbing the spread of SARS-CoV-2 also reduced the circulation of other pathogens. Consequently, both community and hospital demand and consumption of antibiotics dropped sharply during the pandemic (by approximately 20%).

 

2. Reducing contagion risks, hospitals restricted their services to non-COVID patients. Drug shortages in hospitals nearly halved during the pandemic compared to the frequency of shortages in 2018. This uncovered improvement potential in inventory management and demand forecasting.

 

3. In 2022, in an increasing number of countries, SARS-CoV-2 related containment measures ceased. As societies by and large “returned to normal” so did antibiotic consumption. Volatile demand and geographically concentrated production systems led to simultaneous shortages of antibiotics across many parts of the world.

Background

1. Supply disruption of medications in general, and antibiotics in particular, are not a new phenomenon. Since 2014, they have steadily increased in frequency and severity. In the vast majority of cases, it was possible to resolve these shortages by finding suitable substitutes and thereby reduce negative impacts on patients.

 

2. The consumption of antibiotics declined in many European countries between 2011 and 2018. This is welcome as it reduces the build-up of antimicrobial resistance.

 

3. These trends in antibiotics demand coincided with structural transformations in the antibiotics production system. Overall, there is a clear trend of increasing geographic concentration of production. Production sites in China and India have benefitted from this trend.

Policy considerations to avoid antibiotic shortages in the future

1. There are short-term and long-term remedies. Short-term remedies include improvements in the data, planning and forecasting infrastructure. This will require additional investments. Supply chain disruptions can reflect market structure problems. Long-term policies address the market structure and the international division of labour.

 

2. Existing supply networks arise from market processes that reflect a competitive combination of qualities and prices. Deviating from market results comes at a cost which can be interpreted as an insurance premium that health agencies need to incur to avoid impacts on patients. Additional costs require appropriate financing. Ideally, a well-designed market should internalise the risk of disruption, e.g., through appropriate contracts with the adequate incentive structures.

 

3. Antibiotics shortages need to be considered against the backdrop of the global risk of antimicrobial resistance. Ideally, policy remedies should address both issues.

Remedies

1. Understand the scope of the problem. Data availability is an issue. Efforts need to be undertaken to not only track and forecast drug shortages, but to focus on shortages of non-substitutable drugs.

 

2. Demand forecasting and stable supplier relationships. Health authorities need to better understand the demand developments for antibiotics in the population. Evidence-driven demand planning could form the basis for building stable supply relationships, e.g., through multiyear contracts with producers that contain robust provisions in case of non-delivery.

 

3. Capacity markets and excess inventory. In case of emergencies, add-on production capacities that timely provide the drugs in question may address arising shortages from the outset.

 

4. Single Market. The European Union provides a powerful tool to mitigate supply risks across multiple players through the Single Market. Coordinated and more centralised EU inventories can also help to reduce overall safety stock and thereby avoid inefficiencies.

 

5. Bargaining power. Countries, regions, or health agencies might consider deeper cooperation and pursue joint forecasting and joint procurement strategies. Adverse effects on the market structure of suppliers and possibly anti-competitive behaviour of suppliers need to be monitored.

 

6. Diversification of supply. Diversification requires internationally competitive producers. Hence, the debate about broadening the supplier base is embedded in a wider discussion about competitiveness and structural change.

 

7. Subsidised procurement prices. Reimbursement models that delink development costs from unit sales have been proposed to tackle drug shortages.


Event

CSH Talk by Thomas Choi "Supply Networks: Dyads, Triads, Tetrads, and Beyond"


Jun 06, 2023 | 15:0016:00

Complexity Science Hub Vienna

Publication

V.D.P. Servedio, M. R. Ferreira, N. Reisz, R. Costas, S. Thurner

Scale-free growth in regional scientific capacity building explains long-term scientific dominance

Chaos, Solitons & Fractals 167 (2023) 113020

Press

Obesity increases the chances of developing mental disorders for all age groups


News Medical, May 30, 2023

Publication

A. Nerpel, et al.

SARS-ANI: a global open access dataset of reported SARS-CoV-2 events in animals

Scientific Data 9 (438) (2022)

Research News

May 30, 2023

Obesity increases risk of mental disorders throughout life

People

May 30, 2023

Meet Sachin Rawat

Publication

C. Deischinger, E. Dervic, S. Nopp, M. Kaleta, P. Klimek, A. Kautzky-Willer

Diabetes mellitus is associated with a higher relative risk for venous thromboembolism in females than in males

Diabetes Res Clin Pract. (2022) 36471550

News

May 31, 2023

Forensic analysis shows signs of election fraud in Turkey

Press

End Times by Peter Turchin review – can we predict the collapse of societies?


The Guardian, May 28, 2023

Press

Wie Medikamente durch die Welt reisen


NEWS, May 31, 2023

Event

CSH Talk by François Lafond "Firm-level production networks: what do we (really) know?"


Jun 07, 2023 | 15:0016:00

Complexity Science Hub Vienna

News

May 31, 2023

Forensic analysis shows signs of election fraud in Turkey

People

May 30, 2023

Meet Sachin Rawat

Research News

May 30, 2023

Obesity increases risk of mental disorders throughout life

News

May 25, 2023

Quotas alone will not solve the problem

Spotlight

May 17, 2023

Complexity Research for Digital Humanism

People

May 12, 2023

Peter Turchin introduces his new book

Research News

May 2, 2023

Scientists create high-resolution poverty maps using big data

News

Apr 26, 2023

BEYOND COLLECTIVE STUPIDITY

Spotlight

Apr 21, 2023

How does a region become a center for innovation?

Spotlight

Apr 14, 2023

Are cars our kings?

Press

End Times by Peter Turchin review – can we predict the collapse of societies?


The Guardian, May 28, 2023

Press

Obesity increases the chances of developing mental disorders for all age groups


News Medical, May 30, 2023

Press

Wie Medikamente durch die Welt reisen


NEWS, May 31, 2023

Press

Kritik an EU-Chatkontrolle


Ö1 | Digital.leben, May 11, 2023

Press

Treibjagd im Darknet: Neue Technologien für Cyber-Ermittler


Salzburger Nachrichten, May 16, 2023

Press

„Die Älteren halten zu Erdogan, die jüngere Generation hat andere Sorgen“


Cicero, May 9, 2023

Press

Stablecoin Destabilization - why should we care?


Forbes, Apr 27, 2023

Press

„Wir sind nicht so einfach zu manipulieren“ [feat. Hannah Metzler]


Kurier, Apr 29, 2023

Press

Die manchmal fatale Lust, alles selbst zu recherchieren [feat. Mirta Galesic & Henrik Olsson]


Die Presse, Apr 14, 2023

Press

La scienza ha creato una nuova classificazione delle aperture degli scacchi [ital | feat. Vito Servedio & Giordano De Marzo]


WIRED, Apr 10, 2023

Publication

R. Prieto-Curiel, J. E. Patino, B. Anderson

Scaling of the morphology of African cities

PNAS 120 (9) (2023) e2214254120

Publication

A. Di Natale, D. Garcia

LEXpander: applying colexification networks to automated lexicon expansion

Behaviour Research Methods (2023)

Publication

V.D.P. Servedio, M. R. Ferreira, N. Reisz, R. Costas, S. Thurner

Scale-free growth in regional scientific capacity building explains long-term scientific dominance

Chaos, Solitons & Fractals 167 (2023) 113020

Publication

C. Deischinger, E. Dervic, S. Nopp, M. Kaleta, P. Klimek, A. Kautzky-Willer

Diabetes mellitus is associated with a higher relative risk for venous thromboembolism in females than in males

Diabetes Res Clin Pract. (2022) 36471550

Publication

A. Nerpel, et al.

SARS-ANI: a global open access dataset of reported SARS-CoV-2 events in animals

Scientific Data 9 (438) (2022)

Publication

E. D. Lee, X. Chen, B. C. Daniels

Discovering sparse control strategies in neural activity

PLoS Computational Biology (May 27) (2022)

Publication

H. Kong, S. Martin-Gutierrez, F. Karimi

Influence of the first-mover advantage on the gender disparities in physics citations

Communications Physics 5 (243) (2022)

Publication

T.M. Pham, J. Korbel, R. Hanel, S. Thurner

Empirical social triad statistics can be explained with dyadic homophylic interactions

PNAS 119 (2022) e2121103119

Publication

G. De Marzo, V.D.P. Servedio

Quantifying the complexity and similarity of chess openings using online chess community data

Scientific Reports 13 (2023) 5327

Publication

D. R. Lo Sardo, S. Thurner, et al.

Systematic population-wide ecological analysis of regional variability in disease prevalence

Heliyon 9(4) (2023) e15377

Publication

J. Wachs

Digital traces of brain drain: developers during the Russian invasion of Ukraine

EPJ Data Science 12 (2023) 14

Publication

D. Diodato, R. Hausmann, F. Neffke

The impact of return migration on employment and wages in Mexican cities

Journal of Urban Economics 135 (2023) 103557

Event

CSH Talk by Thomas Choi "Supply Networks: Dyads, Triads, Tetrads, and Beyond"


Jun 06, 2023 | 15:0016:00

Complexity Science Hub Vienna

Event

CSH Workshop: "Firm-level supply network data for policy making"


Jun 05, 2023 | 8:00Jun 06, 2023 | 17:00

Complexity Science Hub Vienna

Event

CSH Talk by François Lafond "Firm-level production networks: what do we (really) know?"


Jun 07, 2023 | 15:0016:00

Complexity Science Hub Vienna